Two Sigma Securities’s Acadia Pharmaceuticals ACAD Stock Holding History

Two Sigma Securities’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-19,600	Closed	-$838K	–	1282
2019 Q4	$838K	Buy	19,600 +500	+3%	+$21.8K	0.01%	1137
2019 Q3	$687K	Buy	+19,100	New	+$579K	0.01%	1043
2019 Q2	–	Sell	-9,900	Closed	-$266K	–	2041
2019 Q1	$266K	Buy	+9,900	New	+$231K	﹤0.01%	1271

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Two Sigma Securities's ACAD Position: Q1 2020 in Review

Two Sigma Securities sold out of Acadia Pharmaceuticals (ACAD) in Q1 2020, closing a stake of 7,269 shares — an estimated $311K sold.

Two Sigma Securities first reported a position in ACAD in Q2 2017 and held it in 4 quarters. The position peaked at $359K in Q3 2019. 246 funds tracked by Wall St. Rank hold ACAD as of Q1 2020.

Two Sigma Securities reported no remaining Acadia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Two Sigma Securities sold 7,269 Acadia Pharmaceuticals shares in Q1 2020, an estimated $311K.
Two Sigma Securities first reported a position in Acadia Pharmaceuticals in Q2 2017 and held it in 4 quarters.
Two Sigma Securities's Acadia Pharmaceuticals position peaked at $359K in Q3 2019.
246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2020.

Based on Two Sigma Securities's 13F filing for Q1 2020, filed 15 May 2020.